Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXB99Y
|
||||
Drug Name |
(R)-6-Hydroxycarbamoyl-5-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-hexanoic acid
|
||||
Synonyms |
CHEMBL85933
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C18H25N3O6
|
||||
Canonical SMILES |
CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCC(=O)O)CC(=O)NO
|
||||
InChI |
InChI=1S/C18H25N3O6/c1-19-18(26)14(10-12-6-3-2-4-7-12)20-17(25)13(11-15(22)21-27)8-5-9-16(23)24/h2-4,6-7,13-14,27H,5,8-11H2,1H3,(H,19,26)(H,20,25)(H,21,22)(H,23,24)/t13-,14+/m1/s1
|
||||
InChIKey |
NBDGYUOAVSOSOD-KGLIPLIRSA-N
|
||||
Target and Pathway | |||||
Target(s) | Interstitial collagenase | Target Info | [1587926] | ||
Neutrophil collagenase | Target Info | [1587926] | |||
WikiPathways | TGF beta Signaling Pathway | ||||
Bladder Cancer | |||||
Activation of Matrix Metalloproteinases | |||||
Degradation of collagen | |||||
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
Oncostatin M Signaling Pathway | |||||
Prostate Cancer | |||||
Integrated Breast Cancer Pathway | |||||
Integrated Cancer pathway | |||||
Cell surface interactions at the vascular wall | |||||
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases | |||||
Matrix Metalloproteinases | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.